SVB Wealth’s Structure Therapeutics GPCR Stock Holding History

SVB Wealth’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-836	Closed	-$14.5K	–	973
2025 Q1	$14.5K	Buy	+836	New	+$20.5K	﹤0.01%	811

Other funds holding GPCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SVB Wealth's GPCR Position: Q2 2025 in Review

SVB Wealth sold out of Structure Therapeutics (GPCR) in Q2 2025, closing a stake of 836 shares — an estimated $14.5K sold.

SVB Wealth first reported a position in GPCR in Q1 2025 and held it in 1 quarter. The position peaked at $14.5K in Q1 2025. 172 funds tracked by Wall St. Rank hold GPCR as of Q2 2025.

SVB Wealth reported no remaining Structure Therapeutics position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 836 Structure Therapeutics shares in Q2 2025, an estimated $14.5K.
SVB Wealth first reported a position in Structure Therapeutics in Q1 2025 and held it in 1 quarter.
SVB Wealth's Structure Therapeutics position peaked at $14.5K in Q1 2025.
172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.